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Hydroxyapatite (HAP) is a biocompatible ceramic that is currently used in a number of current biomedical
applications. Recently, nanometre scale forms of HAP have attracted considerable interest due to their close
similarity to the inorganic mineral component of the bone matrix found in humans. In this study ultrafine
nanometre scale HAP powders were prepared via a wet precipitation method under the influence of
ultrasonic irradiation. The resulting powders were compacted and sintered to form a series of ceramic
pellets with a sponge-like structure with varying density and porosity. The crystalline structure, size and
morphology of the powders and the porous ceramic pellets were investigated using advanced
characterization techniques. The pellets demonstrated good biocompatibility, including mixed cell
colonisation and matrix deposition, in vivo following surgical implantation into sheep M. latissimus dorsi.
E
very year millions of people worldwide require a bone transplant and the preferred bone replacement
procedure involves the use of an autograft material (patient’s own bone) since it displays excellent bio-
compatibility, osteogenic properties and delivers bone forming cells to the implant site. Today, the medical
use of autografts is well established with good clinical outcomes and as a result the procedure is considered the
gold standard for bone transplantation. However, problems such as donor site morbidity and the limited source of
potential donor sites have caused researchers in the field to look for alternative sources of bone tissue1–4. The use of
alternative materials such as allogenic bone grafts (sourced from another donor) generally results in a significant
response from the body’s immune system, while disease transmission resulting from this procedure is potentially
a serious side effect5. Furthermore, obtaining bone tissue for an allograft procedure is complicated by medical,
ethical and legal concerns. Moreover, both autograft and allograft procedures also suffer from a limited supply of
high quality bone tissue for suitable medical use.
An attractive alternative to natural bone grafts is to create synthetic materials that can be formed into implants
or scaffolds for bone regeneration. The engineered scaffold needs to create a porous architectural structure, which
effectively replicates the various physical, chemical and mechanical properties found in natural bone tissue.
Therefore, the scaffold material needs be biologically compatible, i.e. it should be nontoxic to the body tissues6–8,
non-immunogenic, and have a degradation rate synchronized with the formation of new tissues9. The advantage of
the balanced degradation rate is that it will allow the invading cells to steadily colonise the scaffold and at the same
time permit the formation of blood vessels necessary for the delivery of nutrients to the forming bone tissues. Other
important properties of the scaffold should include: 1) an internal architecture consisting of suitably sized inter-
connecting pores that mimic the structure of trabecular bone10,11; 2) the internal surface area of the inter-connect-
ing pore structure should be optimised for maximum cell coverage; 3) the surface chemistry of the scaffold material
should maximize cell and tissue adhesion; 4) the material should be capable of being sterilized; and 5) material
should also be mechanically strong enough to withstanding normal physical loading encountered in vivo12–14.
Due to the close chemical similarity of synthetic hydroxyapatite (HAP) to the natural form found in the
inorganic component of the bone matrix, there have been extensive research efforts into employing synthetic
HAP as a bone substitute in a number of clinical applications such as bone augmentation, coating metal implants
and filling components in both bone and teeth15–19. The most important factor that must be addressed to achieve a
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For example, the material should not induce any cytotoxicity,
immunological reactions, and inflammatory responses from the
body6–8. The four main features that make synthetic HAP attractive
for clinical applications are: 1) it has good biocompatibility with
tissues such as skin, muscle and gums20; 2) its biodegradability in situ
is slow; 3) it provides good osteoconductivity; and 4) it offers good
osteoinductivity capabilities16,21,22. Furthermore, due to its excellent
biocompatibility, dispersed nanometre scale HAP and similar calcium
phosphate particles have found new and novel medical applications
such as carriers in biological systems for the transfer of nucleic acids
and therapeutic drugs23,24. It was because of these highly attractive
features of synthetic HAP that it was selected as the scaffold material
for present study. Therefore, the three aims of this study were firstly to
form a set of ceramic pellets with a sponge- like structure with varying
density and porosity from a nanometre scale HAP powder and micro-
metre scale porogen. Secondly, the physical and chemical properties
of pellets were studied using advanced characterization techniques
and finally using a pilot in vivo study to investigate the biocompat-
ibility of the pellets for potential tissue regeneration applications by
surgical implantation into sheep M. latissimus dorsi.
Results
XRD spectroscopy analysis. XRD pattern analysis was used to
identify the purity and crystalline size of the synthesised nanome-
tre scale HAP powders and the particle size of the HAP based ceramic
pellets sintered at temperatures of 650uC, 850uC, 1050uC and
1250uC, as shown in Figure 1 (a). Analysis of all XRD patterns,
except the 1250uC pattern revealed the presence of crystalline
nanometre scale HAP phases. These phases were found to be
consistent with the phases listed in the ICDD database, with the
main (h k l) indices for nano-HAP: (002), (211), (300), (202),
(130), (002), (222) and (213) being indicated. However, the
diffraction pattern for the 1250uC sample indicated that significant
decomposition of the HAP phase had taken place. The
decomposition of HAP in atmospheric air at elevated temperatures
was reported and discussed by Liao et al25. Their study revealed that
during gradual heating from 1000 to 1360uC, HAP steadily releases
its OH2 ions and transforms into crystalline oxyhydroxyapatite
(OHAP). Above 1360uC, Liao et al also found that the OHAP
would decompose into a tetra calcium phosphate (TTCP) and a-
tricalcium phosphate (a-TCP) phase. The products seen in the
1250uC XRD pattern consist of a significantly reduced HAP
component, sizeable amounts of b-tricalcium phosphate (b-TCP)
and the presence of small amounts of potassium calcium hydrogen
phosphate and potassium calcium phosphate (Detailed XRD pattern
is presented in supplementary information).
The crystalline size, t(hkl), of the ultrafine HAP powders and sam-
ples from the sintered HAP based pellets was calculated from the
respective XRD patterns using the Debye-Scherrer equation26–28
t hklð Þ~
0:9l
B cosh hklð Þ
ð1Þ
Figure 1 | XRD and TEM analysis. (a) XRD spectrum of synthesised nano-HAP powder and sample powders taken from thermally treated pellets at
various sintering temperatures (b) TEM micrograph of synthesized nanometre scale HAP powder (c) TEM micrograph of particles sintered at 850uC (d) a
graph showing particle growth with increasing sintering temperature.
www.nature.com/scientificreports
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where, l is the wavelength of the monochromatic X-ray beam, B is
the Full Width at Half Maximum (FWHM) of the peak at the max-
imum intensity, h(hkl) is the peak diffraction angle that satisfies
Bragg’s law for the (h k l) plane and t(hkl) is the crystallite size. The
crystallite size calculated from the (002) reflection peak for the pow-
der gave a mean value of 30 nm, while the mean particle size for the
sintered samples ranged from 323 nm for the 650uC up to 1224 nm
for the 1250uC sample. The degree of crystallinity and the subsequent
growth in particle size has a significant influence on the material’s
properties such as density and porosity. Hence, the percentage crys-
tallinity of the material was calculated using the equation proposed
by Landi et.al29, see equation 2.
XC~1{ V112{300=I300ð Þ ð2Þ
where XC is the percentage crystallinity of the material, V112-300 is the
intensity of the trough between (112) and (300) peaks and I300 is the
intensity of (300) peak. The crystallinity of the powder was estimated
to be 48.17%. Subsequent analysis revealed that the sintering process
promoted both particle growth and enhancement of crystallinity in
the pellets as seen in Figures 1 (d) and 2 (c).
FESEM and TEM microscopy analysis. The size and morphology of
both the nanometre scale HAP powders and the structure of various
sintered pellets was investigated using both TEM and FESEM. A
typical TEM micrograph of the ultrafine powder is presented in
Figure 1 (b) and reveals the presence of a spherical particle morpho-
logy, which is similar to the particle morphologies reported in the
literature30–34. The mean particle size determined from TEM analysis
was found to be 28 6 5 nm, which was comparable to the mean value
of 30 nm calculated from the XRD spectra. Both TEM and FESEM
techniques were used to determine the size and morphology of the
particles produced in the pellets during the sintering process. A
typical TEM micrograph taken of particles produced during
sintering at 850uC is presented in Figure 1 (c), while the results of
a particle size distribution analysis for the 850uC samples are
presented in Figure 2 (b). The particle analysis revealed a mean
particle size of 538 nm 6 120 nm, which closely matched the
results of TEM (550 nm 6 150 nm) and FESEM (Figure 2 (a))
with a mean particle size of 518 nm 6 140 nm. Analysis of all
pellets sintered at various sintering temperatures (650uC, 850uC,
1050uC and 1250uC) revealed that the increased temperatures
produced an increase in particle size and a morphological structure
becoming more angular, cubic and rectangular in nature. The results
of the particle size analysis were similar to findings of the XRD
analysis with the mean particle size ranging from 376 nm for the
650uC up to 1318 nm for the 1250uC (Figure 1 (d)). However, at the
higher sintering temperature of 1250uC, the morphology and much
greater particle size diversity confirmed HAP decomposition
identified in the XRD analysis.
The FT-IR spectroscopy analysis. Inspection of a typical FT-IR
spectrum of synthesized ultrafine powder is presented in Figure 3
(b) and reveals the presence of several bands associated with nano-
metre scale HAP. Starting from the right hand side of the spectrum,
the first two bands encountered are 564 cm21 and 601 cm21, which
are the result of n4 vibrations being produced by the O-P-O mode.
The next two bands located at 725 cm21 and 832 cm21, (each with a
low transmittance) are associated with the carbonate group and
clearly indicate the presence of carbonates in the samples. The
961 cm21 band results from the n1 symmetric stretching vibrations
of the P-O mode. While the very strong peaks located at 1032 cm21
and 1092 cm21 correspond to the PO432 functional group (P-O
mode) and the weaker peak at 1384 cm21 corresponds to the
CO223 functional group. The carbonate formation most likely
results from the interaction between atmospheric carbon dioxide
and the alkaline HAP precursor solution during the synthesis
Figure 2 | Particle size analyses. (a) FESEM image of HAP sample sintered at 850uC (b) a typical particle size profile showing particle size distribution for
850uC. The effect of increasing sintering temperature on: (c) Surface area and crystallinity and (d) Porosity and density.
www.nature.com/scientificreports
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process35–37. The smaller peak located at 1644 cm21 also corresponds
to a CO223 group. The band located at 3432 cm21 indicates the
presence of absorbed water, while the weak peak at 3570 cm21
corresponds to the vibrations of OH2 ions in the HAP lattice. The
results of the FT-IR analysis clearly indicate that the synthesized
ultrafine powders are HAP.
Energy dispersive X-ray spectroscopy analysis. The EDS spectrum
presented in Figure 3 (c) reveals the presence of two dominant peaks,
namely Ca and P, while on the left hand side of the spectrum, to a
lesser extent is an oxygen peak. Calculation of the Ca/P ratio from the
EDS spectrum gives a value of 1.656, which is very close to the
stoichiometric value of 1.67 used in the ultrasonic process to create
HAP. The close agreement of the Ca/P (approx. 0.84%) not only
confirms the presence of HAP, but also confirms that the HAP
powders produced are of high quality and confirms the results of
the XRD analysis.
Differential thermal and Thermal Gravimetric Analysis. Analysis
of the DTA thermograph presented in Figure 3 (d) reveals that there
were no exothermic or endothermic reactions taking place over the
24 to 980uC temperature range. Furthermore, no phase transforma-
tions occurred over this temperature range, which confirmed the
physical and chemical stability of the HAP powder sample and was
similar to the results of Farzadi et al38. Figure 3 (d) presents a typical
TGA thermograph of a powder sample and reveals a decreasing trend
in sample mass resulting from water loss. The initial sample mass was
18.42 mg and the final mass at the end of the heating cycle was
16.37 mg, indicating a water loss of 2.05 mg (11.3%). Analysis of
the thermograph revealed a three-stage water loss profile over the
temperature range. In the first stage, there was a 2.6% mass loss
observed, indicating the evaporation of surface moisture and
absorbed water. During the second stage, there was a 1% mass loss
observed, while in the final stage there was a sharp 7.7% mass loss
resulting from the loss of lattice water. From 725uC onwards, there
was no further mass loss from the sample indicating the high thermal
stability of the HAP powder up to about 1000uC.
In vitro assessment. Dissolution under physiological conditions of
nanometre scale HAP powder samples was carried out in a
phosphate buffered saline (PBS) solution at 37uC with an initial
solution pH of 7.40. The initial pH of 7.40 was selected because it
is the mean pH value of the extracellular fluid, which is tightly
regulated by buffers to remain within the narrow range of 7.35 to
7.45. After immersion of sample into the PBS solution, both the pH
and Ca21 ion concentration values were recorded at regular time
intervals over a 14 day period as presented in Figure 3 (a). During
this period solution pH steadily decreased from 7.40 to 6.98 (5.7%)
indicating that the solution was becoming less alkaline. However,
natural pH regulation by blood based buffers in vivo would
significantly restrict any variation. During the same assessment
period Ca21 ion dissolution from the sample steadily increases up
to a maximum value of 63 ppm at the end of the test period as seen in
Figure 3 (a). The low dissolution rate of Ca21 ions into the PBS
solution suggests that the relatively small release of ions is not
likely to cause any adverse effects in the body’s ability to maintain
its calcium balance; since osteoclasts routinely resorb bone tissue and
return calcium back to the extracellular fluid.
Figure 3 | Physical and chemical property analyses. (a) In vitro assessment: variation of pH and the release of Ca21 ions from a nano-HAP powder
immersed in a PBS solution over a 14 day period (b) FT-IR spectrum of a synthesised and thermally treated nano-HAP powder (c) EDS spectrum of a
synthesised nano-HAP powder used to confirm chemical composition and calculate the Ca/P ratio (d) TGA and DTA thermograph of the synthesised
nano-HAP powder.
www.nature.com/scientificreports
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Physical property analysis. The results of Brunauer-Emmett-Teller
(BET) surface area analysis, porosity and density studies of the
powder based pellets sintered at temperatures of 650uC, 850uC,
1050uC and 1250uC are presented in Figures 2 (c) and 2(d). The
largest surface area (10.977 m2/g), the highest porosity (53.02%)
and lowest density (1.449 g/cm3) were recorded for the lowest
sintering temperature of 650uC. While the lowest surface area
(1.137 m2/g), lowest open porosity (36.78%) and highest density
(1.952 g/cm3) were recorded for the sintering temperature 1050uC.
The lowest sintering temperature of 650uC had the lowest density
and highest porosity, which tended to produce an open porous
structure. Increasing the sintering temperature promoted particle
growth and produced a significantly reduction in both surface area
and porosity. However, as previously discussed, the sintering
temperature of 1250uC resulted in significant HAP decomposition.
In vivo assessment. Pellet implantation into sheep M. latissimus
dorsi was well tolerated and elicited no pain, gross swelling or
visible immune response. Significant adherence to the surrounding
capsule was found in some specimens, with increased adherence at
12 weeks and also for higher sintered temperature pellets (850uC,
1050uC and 1250uC); in several cases a strongly adherent fibrous
‘pseudo-periosteum’ was noted. Most pellets grossly showed
infiltrated blood-staining suggestive of porosity and vascular
invasion as seen in Figure 4 (b). Histological studies of the
surrounding tissue capsule showed healthy granulation tissue and
myofibre regeneration, with mild focal lymphohistiocytic
inflammation mainly related to areas of fat necrosis (i.e. typical of
a healing surgical wound). Pellets reclaimed at the end of the 4th week
revealed the presence of multinucleated giant cells at the surface of
the pellet as seen in Figures 5 (a) and (b). Optical microscopy
observations revealed that the internal three-dimensional porous
structure of the pellets provided an attractive environment for cells
to infiltrate and colonise as seen in Figure 4 (c). Branching channels
deep within the body of the pellet were in places, lined by flat
squamous cells resembling endothelia (Figures 6 (c) and (d)). By
the end of week 12 both connective tissues and bone matrix were
being formed throughout the pellet, which clearly indicated that the
HAP powder based pellets were highly biocompatible. Collagen
formations were identified as a fibrillar eosinophilic matrix
amongst spindle shaped cells (fibroblasts), having a positive stain
Figure 4 | Analysis of porosity and cell infiltration. (a) A typical surface
image of macro-pores found in ceramic pellets before implantation (b) A
typical surface image of a reclaimed pellet showing infiltration and blood-
staining suggestive of porosity (c) a micrograph showing dense cell clusters
(arrowheads) throughout the body of the implanted pellet and Inset (d)
shows details of lymphocytes with dark round nucleus and scant
cytoplasm, and occasional spindle shaped fibroblastic cells (850uC: H&E.
12 weeks).
Figure 5 | Typical cells present and cellular colonisation of implant. (a)
Multinucleate giant cells (arrows) at edge of a typical HAP implant (b)
enlargement of an individual multinucleate giant cell under 3100 oil
immersion objective (H&E. 12 weeks) (c) dense eosinophilic matrix (bone
matrix – solid arrows) within the body of the implant, amongst non
colonised areas of implant (*), and surrounded by fibrous tissue (d) shows
an area of bone matrix in which individual cells (osteocytes – open arrows)
are present within small cavities (lacunae) (850uC: H&E. 12 weeks).
www.nature.com/scientificreports
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with Martius scarlet blue39 (Figure 6 (a)), and with a birefringent
appearance under crossed polarising filters. Bone matrix (Figures 5
(c), 5 (d) and 6 (a)) was identified as a condensed (hyalinised)
eosinophilic matrix, containing abundant collagen fibres positively
stained (blue) with Martius scarlet blue. The bone matrix (Figure 6
(a)) showed bifringence under crossed polarizing filters, and was
found to be populated by scattered cells (osteocytes) with small
cavities (lacunae) typical of bone (Figure 5 (d)). Other tissue
components that could be mistaken for osteoid include fibrin,
amyloid and degenerate muscle fibres. These were eliminated
because they stain red, rather than blue, with the Martius scarlet
blue stain, and would not have the woven, weakly-birefringent
appearance seen under polarised light40. Some reclaimed pellets
had scattered deposits of round cells with scant cytoplasm
(lymphocytes), at both superficial and deep locations
(multifocally), including the deepest regions of the pellet (Figure 4
(c) and (d)).
Discussion
The ceramic based HAP scaffolds with sponge-like pore structure
were manufactured from nanometre scale HAP powders composed
of spherical 30 nm particles and spherical shaped stearic acid
(,350 mm in diameter), which was used as both binding agent
and porogen. The HAP powders were synthesized using a wet chem-
ical method incorporating ultrasonic irradiation previously
developed and optimized by the authors since the technique allowed
particle size selection41,42. The powders were characterized using
XRD and TEM to determine crystallinity, particle size, and phases
present. EDS and FT-IR were used to determine the Ca/P ratio and
identify functional groups present in the samples, while both TGA
and DTA analysis confirmed the thermal stability of the HAP pow-
ders up to 1000uC. HAP is conventionally sintered at high tempera-
tures (,1000uC) and results in grain growth and densification to
form a solid bioceramic43. Lower temperatures generally produce
ceramics with smaller grain sizes, but are generally unstable and
rapidly deteriorate under load. However, studies have found that
grain size directly influences the cellular interactions and functions
of both osteoblasts and osteclasts44–46. It is for this reason that a
number of studies have looked at producing bioceramics sintered
at temperatures ranging from 650 to 900uC47,48, while other studies
have looked at producing bioceramics without sintering49. Because of
the strong influence of particle size on cell-material interactions, the
sintering temperature in this study started with the lowest feasible
temperature of 650uC and was raised up to 1250uC. All pellets sin-
tered at 650uC, 850uC, 1050uC and 1250uC for 2 h in air were struc-
turally stable and therefore suitable for surgical implantation into
sheep M. latissimus dorsi. However, analysis of XRD patterns for
samples taken from pellets sintered at 1250uC revealed significant
HAP decomposition. The decomposition resulted from the release of
OH2 ions from the HAP lattice structure occurring above 1000uC23
and produced significant amounts of b-tricalcium phosphate (b-
TCP) in addition to the presence of remaining HAP. Also detected
at 1250uC was the presence of small amounts of potassium calcium
hydrogen phosphate and potassium calcium phosphate. The source
of the potassium originated from the potassium di-hydrogen phos-
phate used during the synthesis of the HAP. The indexed XRD pat-
tern of the products produced at 1250uC can be found in the
supplementary information.
After sintering, the resulting sponge-like scaffolds sintered at 650,
850 and 1050uC were HAP, structurally stable and displayed increas-
ing trends in particle size and density. Meanwhile, porosity and BET
surface area of the pellets decreased with increasing temperature.
Examination of microscopic images from various pellets reveals a
matrix with a wide range of pores sizes. For example, Figure 4 (a)
presents a typical surface image of the 850uC pellet showing a variety
of pore sizes. The largest pore diameter seen was 350 mm, with a wide
variety of smaller pores diameters down to 75 mm. The pore size is of
particular biological importance since cells must be able to infiltrate
and colonise the scaffold for effective tissue regeneration to take
place. The ideal pore size recommended for cellular growth and bone
in-growth ranges from 100 to 1000 mm43, with some researchers even
suggesting that pore sizes of at least 300 mm are needed for effective
bone tissue formation and blood capillary development50. Therefore,
cell infiltration and subsequent colonisation of a scaffold are essential
parameters for effective tissue regeneration and ultimately lead to a
successful clinical outcome. The reclaimed pellets all showed signs of
infiltrated blood-staining suggestive of porosity and vascular inva-
sion, with the lower sintering temperatures of 650uC and 850uC
showing the most staining. For example, Figure 4 (b) shows wide
spread blood-staining over the surface of the 650uC pellet indicating
its porous structure. Furthermore, histological inspection of the
micro-section images of the various pellets reveal a pore structure
with a large surface area to bulk volume ratio, with extensive inter-
connecting networks of flow channels throughout the matrix. This
sponge-like pore structure, (as confirmed by the density and porosity
investigations) which mimics trabecular bone is comparable to struc-
tures produced by other researchers and has similar properties such
Figure 6 | Tissue in-growth and vessel-like structures. (a) Tissue in-
growth, within the body of the implant, including areas of bone (solid
arrows) and fibrous tissue (open arrows) amongst small foci of non
colonised implant matrix (*) (Martius scarlet blue. 12 weeks) (b) Inset
shows fibroblastic cells amongst fibrous stroma (arrowheads) (H&E. 12
weeks) (c) tissue in-growth within the body of the implant, in the form of
branching vessel-like structures (solid arrows) (d) endothelial-like cells
(open arrows) lining the apparent vessels (850uC: H&E. 4 weeks).
www.nature.com/scientificreports
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as large pores and extensive porosities51,52. The importance of pore
size and inter-connectivity is crucial in biomedical applications:
allowing cell migration, vascularisation, promoting the diffusion of
nutrients and the removal of metabolic wastes resulting from cellular
activities53. All reclaimed pellets show signs of cell colonisation and
cellular activity, with the 650uC and 850uC pellets showing the most
colonisation activity. The colonisation activity seen in these two
pellets was the direct result of the high porosities (650uC (53%)
and 850uC (47%)) and the inter-connecting channel structure
formed during sintering. Pellets sintered at 1050uC were found to
have porosity of around 37% and also displayed a similar channel
structure, which permitted cell infiltration and colonisation to a
lesser extent.
At the end of week 12, histological studies of all sintered pellets
(650uC, 850uC, 1050uC and 1250uC) revealed that cells could be seen
throughout the scaffold matrix (Figure 4 (c)), which suggests that the
cells are travelling through the matrix via the inter-connecting pore
structure. This inter-connecting structure of pore channels consists
of different pore sizes and geometries. Pore diameters as large as
150 mm can be seen in Figure 4 (c), while in Figure 6 (d) diameters
as small as 20 mm are present. In particular, cells could be seen lining
the channel-like pores in the inner regions of the scaffold (Figure 6
(c) and (d)) proving that the inter-connecting pore structure was
suitable for in vivo cell colonisation. Furthermore, the presence of
new collagen and large areas of new bone could be seen throughout
the internal matrix of the various pellets including infiltration by
lymphocytes in some samples (Figure 4 (d)). Also seen were numer-
ous scattered cells (osteocytes) with small cavities (lacunae) present
in the bony matrix (Figure 5 (d)). The ability to support collagenous
and bony matrix deposition, as well as to allow connective tissue and
inflammatory cell infiltration, seen in this in vivo study, clearly
demonstrates the clinical potential of HAP powder based ceramic
pellets for hard tissue regeneration applications. The stimulation of
bone deposition, especially within the surrounding muscle envir-
onment without direct contact with host bone, is an interesting find-
ing. Bone formation within muscle is seen in the clinical condition
myositis ossificans, typically secondary to muscle injury, or as het-
erotopic bone due to the effects of bone morphogenetic protein54.
Osteoinduction within muscle has been reported with other solid
materials, such as zinc tricalcium phosphate, in the absence of added
bone morphogenetic protein55.
The results of the histological investigations have shown that HAP
based pellets are capable of being used as an effective tissue scaffold.
The presence of several cell types, including the deposition of a new
bone matrix, suggests that this scaffold has the potential to be used as
a bone graft. The study has shown that cells were capable of infilt-
rating the extensive 3-D inter-connecting pore structure and colonise
the pellet scaffold. All reclaimed HAP based pellets (650uC, 850uC
and 1050uC) at week 12 showed extensive cellular activity and sup-
ported collagenous and bony matrix deposition, as well allowing
connective tissue and inflammatory cells to infiltrate. The presence
of different cell types, other than bone cells also confirms the scaf-
fold’s wider biocompatibility towards other cells. Based on the
encouraging results of this pilot study, further work is planned to
improve and match the physical and mechanical properties of the
pellets with those of natural bone tissue. Once these properties have
been achieved, further in vivo studies, will be carried out to establish
the feasibility of using this scaffold for bone grafts.
Methods
Scaffold material and manufacturing. Combining nanometre scale HAP powder
with Stearic acid, which acted as both binding agent and porogen, formed the
micrometre scale porous structure of the scaffold. An extensive description of the
production route for synthesizing nanometre scale HAP powders and porous
bioceramic materials by the authors is given elsewhere42,56. In brief, HAP synthesis
begins by adding a 40 mL solution of 0.32 M calcium nitrate tetra-hydrate into a
small glass beaker. The pH of the solution is then adjusted to 9.0 by slowly adding and
mixing approximately 2.5 mL of ammonium hydroxide (all chemicals supplied by
Chem-Supply, Australia). Once the pH is stabilized, the solution was then subjected
to ultrasonic irradiation for a 1 h using a Hielscher UP50H 950 W Ultrasound
Processor. After the first hour, a 60 mL solution of 0.19 M potassium di-hydrogen
phosphate was slowly added drop-wise into the first solution while undergoing a
second hour of ultrasonic irradiation. During the second hour, the pH of the solution
was monitored and maintained at 9.0 and the Calcium/Phosphate [Ca/P] ratio
maintained at 1.67. At the end of the second hour, the resulting solution underwent
centrifugation (15,000 g) for 20 minutes at room temperature. The resultant white
precipitate sample was then washed, centrifuged for a further 10 minutes and then
deposited into a fused silica crucible before being thermally treated at 100% power for
40 minutes in a domestic microwave (1100 W at 2450 MHz-LGH Australia). At the
end of the thermal treatment the sample was ball milled until all the agglomerations
were removed to form an ultrafine nano-HAP powder. Meanwhile, stearic acid
(supplied by Sigma-Aldrich, Australia) was ball milled to produce a spherically
shaped particle with a mean particle size of 350 mm. Then a mixture of HAP and
stearic acid [1% wt. of Stearic acid to 99% wt HAP] was mechanical mixed together for
2 h. The blended powder was then cold compressed in a cylindrical mould by a
manually operated single action axial hydraulic ram pressurized to 70 MPa and
maintained at this pressure for 1 h to produce a standard pellet size (diameter 18.60 6
0.05 mm and a length of 18.30 6 0.05 mm). The pellets were then sintered in a
programmable high temperature muffle furnace [Model 60 SL, Kiln Manufacturers of
Western Australia] at treatment temperatures of 650uC, 850uC, 1050uC and 1250uC
for a period of 2 h.
Advanced characterization techniques. Powder X-ray diffraction (XRD)
spectroscopy was recorded at room temperature, using a Siemens D500 series
diffractometer [Cu Ka 5 1.5406 Å radiation source] operating at 40 kV and 30 mA.
The diffraction patterns were collected over a 2h range of 20u to 60u with an
incremental step size of 0.04u using flat plane geometry with 2 second acquisition time
for each scan. The powder XRD spectrum was used to identify the purity of the final
nano-HAP powders and the phases present. The size of the particles in the powders
were calculated using the Debye-Scherrer equation [Equation 1] from the respective
XRD patterns, while a bright field Transmission Electron Microscopy (TEM) study
was carried out using a Phillips CM-100 Electron microscope operating at 80 kV to
confirm particle size and morphology. In addition, the fraction of crystalline phase
(Xc) present in the sintered pellets at various temperatures was calculated using the
crystallinity equation proposed by Landi et al29 [Equation 2]. Field Emission Scanning
Electron Microscopy (FESEM) techniques were used to investigate the size,
morphological and macro-structural features of the samples. All micrographs were
taken using a high resolution FESEM [Zeiss 1555 VP-FESEM] at 3 kV with a 30 mm
aperture operating under a pressure of 1.333 3 10210 mbar. In addition, the
micrometre scale particle size distribution of HAP found in the sintered samples was
found by using a Malvern MastersizerH 3000 (Malvern Instruments Ltd, UK). From
the analysis of the particle size distribution data a general error was determined and
applied to the individual measurements. Pore diameter and distribution throughout
the pellet cross-sections were investigated using an Olympus BX51 compound
microscope (Olympus Optical Co. Ltd., Tokyo, Japan) fitted with a DP 70 camera
attachment.
Fourier Transform Infrared (FT-IR) spectroscopy investigations were carried out
using a Bruker Optics IFS 66 series FT-IR spectrometer. The KBr pellet technique was
used, in which 2 g of nano-HAP powder was mixed with 5–10 g of spectroscopic
grade KBr and then compressed at around 15 kPa to form a disk. All FT-IR spectra
data was recorded in the range from 400 cm21 to 4000 cm21 in steps of 4 cm21. The
resulting spectra were then analysed using the OMNICH software package. Energy
Dispersive Spectroscopy (EDS) was used to provide an elemental analysis of the
samples using an Oxford Instruments energy dispersive system (133 eV resolution),
via a 10 mm2 SATW detector. The analysis was carried out to verify the results of the
XRD analysis and to calculate the Ca/P ratio of the synthesised nano-HAP powders.
Thermal Gravimetric Analysis (TGA) and Differential Thermal Analysis (DTA) were
carried out using a Perkin Elmer Simultaneous Thermal Analyzer STA 6000. The scan
cycle started from room temperature and steadily increased temperature at a rate of
15uC/min up to a maximum temperature of 980uC. TGA was used to find weight loss
during the heating cycle, while DTA was used to investigate potential exothermic or
endothermic reactions and potential phase transformations.
Physical property characterization. The density and porosity were determined
firstly by dimensional and mass measurements and secondly by Archimedes’
principle. Dimensions of each pellet were measured using a micrometer (Mitutoyo
M210-25) and their respective weights measured using an Ohaus PA214C
microbalance. The porosity was then determined from the difference in the
theoretical density of HAP (3.16 g/cm3) and the apparent density. The second
technique determined porosity by immersing a previously vacuum dried pellet into a
small beaker containing a solution of Milli-QH water (18.3 MV cm21) produced by an
ultrapure water system [Barnstead Ultrapure Water System D11931; Thermo
Scientific, Dubuque, IA] for a period of 2 hours. The pellet was then removed from
the solution, weighed and then submerged back into the Milli-QH water and its weight
was measured. The Brunauer-Emmett-Teller (BET) surface area measurements of the
nano-HAP powders were carried out by the Australian Commonwealth Scientific and
Industrial Research Organisation’s (CSIRO) Particle Analysis Services laboratory
(PAS) in Perth, Western Australia.
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In vitro assessment. Dissolution under physiological conditions of the ultrafine
nano-HAP powders was carried out in a phosphate buffered saline (PBS) solution,
with the pH adjusted to 7.4. The solution was then sterilized by autoclaving at 120uC
for 20 minutes, before being allowed to cool to room temperature and then stored.
Powder samples were added to the PBS solution, which was then gently stirred and
maintained at 37uC for the study period. Both the solution pH and Ca21 ion
concentration levels were monitored over the 14 day study period. The pH of each
sample solution was measured using a Smith Electronics Q1416 metre. The sample
solution was then filtered using a 0.2 mm membrane and then centrifuged at 15,000 g
for 20 minutes. An equal amount of PBS was then added to the stock solution to
maintain the initial volume. After filtration and centrifuging, the Ca21 ion
concentration in the sample solution was measured using a Varian Vista Axial CCD:
ICP-AES inductively coupled plasma atomic emission spectrometer.
In vivo assessment and histology. An in vivo implantation study was carried out in
sheep (3–4 year old non-pregnant Merino ewes) with the approval of Murdoch
University’s Animal Ethics Committee (R2298/09), and all experiments were
conducted in accordance with the Australian National Health and Medical Research
Council’s (NHMRC) Code of Practice for the care and use of animals for scientific
purposes. In accordance with the ethical principles of the Code (reduce/re-use), the
sheep were simultaneously used in an unrelated trial involving surgery of the stifle
joints (AEC R2042/07). Under general anaesthetic and using full sterile procedure,
four steam-sterilised nano-HAP pellets each of different sinter temperatures (650,
850, 1050 and 1250uC) were surgically implanted into adjacent pockets created by
blunt dissection within the right M. latissimus dorsi muscle of the four sheep. The
muscle pocket, subcutis and skin were then closed using synthetic absorbable sutures
and antibiotic prophylaxis provided (1 g cephalexin sodium). After recovery, the
sheep were accommodated on free-range pasture with some supplementary grain
feeding. Pellets were harvested at 4 weeks and 12 weeks post-implantation (2 sheep
per time point), after humane euthanasia for the above-mentioned projects.
Reclaimed pellets were carefully dissected and manually tested for adherence to the
surrounding tissue capsule. The samples were fixed in 10% neutral-buffered formalin
and processed for routine histology. The pellets and any adherent tissue were fixed in
formalin before being routinely processed through paraffin wax and sectioned at
4 mm thickness. For light microscopy and polarising light microscopy, dissected
pellets were fixed in formalin, decalcified in 5% nitric acid, processed routinely
through paraffin wax, and sectioned at 4 mm before staining with haematoxylin and
eosin, or Martius scarlet blue. A specialist veterinary pathologist evaluated the
sections qualitatively and with some subjective semi-quantitative assessments.
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